Three Biotechs That Are Top Takeover Targets

Eli Lilly (NYSE:LLY | LLY Price Prediction) is the stock everyone wants to talk about, and the reasons are obvious: Mounjaro revenue jumped 125% to $8.66 billion last quarter, the company raised full-year revenue guidance to $82 to $85 billion, and the market cap now sits at roughly $881.8 billion.

24/7 Wall Street • May 18, 2026

Lilly completes acquisition of Verve Therapeutics to advance one-time treatments for people with high cardiovascular risk

INDIANAPOLIS , July 25, 2025 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced the successful completion of its acquisition of Verve Therapeutics, Inc. (Nasdaq: VERV). Verve is a Boston-based clinical-stage company developing genetic medicines for cardiovascular disease.

PRNewsWire • Jul 25, 2025

Lilly and Verve announce expiration of Verve tender offer

INDIANAPOLIS , July 24, 2025 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) and Verve Therapeutics, Inc. (NASDAQ: VERV) today announced that the tender offer to purchase all of the issued and outstanding shares ("Shares") of Verve's common stock in exchange for (i) $10.50 per Share, net to the stockholder in cash, without interest and less any applicable tax withholding, plus (ii) one non-tradable contingent value right ("CVR") per Share, which represents the contractual right to receive a contingent payment of up to $3.00 per CVR, net to the stockholder in cash, without interest and less any applicable tax withholding, upon the achievement of a certain specified milestone (the "Offer"), expired as scheduled at one minute past 11:59 p.m., Eastern time, on July 23, 2025 and was not extended (such date and time, the "Expiration Time").

PRNewsWire • Jul 24, 2025

3 Bullish Biotech Stocks With Explosive Growth Trends

Investing in biotechnology stocks is similar to the drug development process itself. That is, investors frequently experience long periods of nothing much happening, interrupted by periods of sharp movement.

MarketBeat • Jul 21, 2025

Why Lilly's Bid for Verve Therapeutics Sent the Stock Soaring This Week

Shares in Verve Therapeutics (VERV -0.54%) soared 80.5% this week on the news of an agreement for Eli Lilly (LLY -2.60%) to acquire Verve. The deal centers on an exciting cardiovascular health medicine program, VERVE-102.

The Motley Fool • Jun 20, 2025

$HAREHOLDER ALERT: Class Action Attorney Juan Monteverde Investigates the Merger of Verve Therapeutics, Inc. (NASDAQ: VERV)

NEW YORK, June 20, 2025 (GLOBE NEWSWIRE) -- Class Action Attorney Juan Monteverde with Monteverde & Associates PC (the “M&A Class Action Firm”), has recovered millions of dollars for shareholders and is recognized as a Top 50 Firm in the 2024 ISS Securities Class Action Services Report. The firm is headquartered at the Empire State Building in New York City and is investigating Verve Therapeutics, Inc. (NASDAQ:  VERV ) related to its sale to Eli Lilly. Under the terms of the proposed transaction, Verve shareholders will receive $10.50 per share in cash, plus one non-tradeable contingent value right per share entitling the holder to receive up to an additional $3.00 per share upon the achievement of certain milestones. Is it a fair deal?

GlobeNewsWire • Jun 20, 2025

VERVE THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Verve Therapeutics, Inc. - VERV

NEW YORK & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Verve Therapeutics, Inc. (NasdaqGS: VERV) to Eli Lilly and Company (NYSE: LLY). Under the terms of the proposed transaction, shareholders of Verve will receive $10.50 per share in cash, plus one non-tradeable contingent value right per share entitling the holder to receive up to an additional $3.00.

Business Wire • Jun 19, 2025

Gene-Editing Stocks Gain on LLY-VERV Deal Announcement

LLY's move to buy Verve ignites investor interest across gene-editing stocks like CRSP, NTLA and BEAM in a booming M&A year.

Zacks Investment Research • Jun 18, 2025

Verve Therapeutics Skyrockets — Pulling Gene-Editing Stocks Higher — On $1.3 Billion Eli Lilly Takeover

Verve Therapeutics stock nearly doubled Tuesday after Eli Lilly agreed to buy the gene-editing company for up to $1.3 billion.

Investors Business Daily • Jun 17, 2025

Why Verve Therapeutics Stock Is Skyrocketing Today

Shares of Verve Therapeutics (VERV 76.24%) were skyrocketing 75.7% higher as of 10:50 a.m. ET on Tuesday.

The Motley Fool • Jun 17, 2025